548 Folgen

  1. How One Drugmaker Reaches out to Communities at Greater Risk for Rare Heart Condition

    Vom: 3.3.2023
  2. A Next-Generation RNA Therapy Targets Telomere Disorders

    Vom: 3.3.2023
  3. BridgeBio Advances Therapy for Limb-Girdle Muscular Dystrophy that Started with Two Patient Families

    Vom: 24.2.2023
  4. Translating Urgency into Science

    Vom: 16.2.2023
  5. Empowering Ultra-Rare Disease Patients to Pursue the Discovery of Treatments

    Vom: 10.2.2023
  6. Why a Topical Cannabidiol Gel May Help Treat the Behavioral Symptoms of Fragile X

    Vom: 2.2.2023
  7. An Ultra-Rare Disease Drug Developer Tries to Navigate Regulatory Uncertainty

    Vom: 26.1.2023
  8. Powering Cells in People with Rare Mitochondrial Diseases

    Vom: 19.1.2023
  9. Powering Weakened and Stressed Cells in ALS to Function Better with Nanocrystal Therapy

    Vom: 12.1.2023
  10. Developing a New Class of Therapies Based on a Natural Cargo Carrier

    Vom: 5.1.2023
  11. Reaching Beyond the Limits of Enzyme Replacement Therapies with Gene Therapies

    Vom: 29.12.2022
  12. One Woman’s Journey as a Caregiver to a Husband with Frontotemporal Dementia

    Vom: 22.12.2022
  13. Treating Rare Endocrine Disorders with Therapeutic Peptides

    Vom: 15.12.2022
  14. Tackling the Pricing Challenges for Advanced Therapies for Rare Diseases

    Vom: 8.12.2022
  15. Addressing the Current Limitations of AAV Gene Therapies

    Vom: 1.12.2022
  16. Examining the Legislative Landscape for Rare Disease Drug Development

    Vom: 24.11.2022
  17. How a Drug Setback Became a Patient Community’s Gain

    Vom: 18.11.2022
  18. Helping Regulators and Drug Developers Understand the Challenges of Living with Fabry Disease

    Vom: 10.11.2022
  19. Addressing Racial Disparities in a Rare Blood Cancer

    Vom: 3.11.2022
  20. How New Sequencing Technology Promises to Alter the Diagnostic Odyssey

    Vom: 27.10.2022

7 / 28

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site